Details

Autor(en) / Beteiligte

• Hung, Chao‐Hung
• Hu, Tsung‐Hui
• Lu, Sheng‐Nan
• Kuo, Fang‐Ying
• Chen, Chien‐Hung
• Wang, Jing‐Houng
• Huang, Chao‐Min
• Lee, Chuan‐Mo
• Lin, Chih‐Yun
• Yen, Yi‐Hao
• Chiu, Yi‐Chun

Titel

Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus

Ist Teil von

• International journal of cancer, 2016-02, Vol.138 (3), p.714-720

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2016

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Hepatocarcinogenesis is a multistep process that evolves from cirrhosis or dysplastic nodule (DN), and eventually leads to overt hepatocellular carcinoma (HCC). Differentiation between early HCC and DN is an important issue in the clinical setting. This study aims to investigate the potential of circulating microRNA (miRNA) levels in the diagnosis of early HCC. RNA was extracted from sera of 30 chronic hepatitis B patients with pathologically proven DN and 120 age‐ and sex‐matched patients with early HCC. Paired samples were collected from ten patients with DN who developed overt HCC in the follow‐up. A panel of ten cancer‐associated miRNAs was analyzed by quantitative real‐time reverse‐transcription polymerase chain reaction. Serum levels of miR‐16, miR‐122, miR‐221, let‐7b and miR‐15b were significantly lower in patients with DN than in the HCC group. When DN progressed to overt HCC, serum miR‐122, miR‐let‐7b and miR‐15b levels increased significantly (p = 0.046, 0.043 and 0.044, respectively). As a single marker, α‐fetoprotein (AFP) and miR‐122 as well as let‐7b had the similar performance for differentiate HCC from DN. As limited to subjects with normal AFP, let‐7b resulted in a sensitivity of 84.8% and a specificity of 50% in separating HCC and DN with a cutoff value of 3.5 (p = 0.001). In conclusion, miR‐122 and let‐7b, which are upregulated in the serum of early‐HCC patients, can be useful markers for differentiating early HCC from DN in chronic hepatitis B patients. What's new? Due to late detection, the prognosis for hepatocellular carcinoma (HCC) is generally dismal. HCC‐specific biomarkers are thus urgently needed, especially in areas where hepatitis B is endemic. In this study, the authors found that serum levels of certain microRNAs (miRNAs) are significantly higher in patients with early HCC, compared to those with dysplastic nodules of the liver. These specific miRNAs may therefore provide a useful screening tool for early detection of HCC, which could greatly improve treatment outcomes.